Company news
Enliven Therapeutics, Inc. news in 2020
Enliven Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
December 6, 2020
Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
November 29, 2020
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory
November 16, 2020
Imara Reports Third Quarter 2020 Financial Results and Business Highlights
November 4, 2020
Imara to Webcast Conference Call of Third Quarter Financial Results
October 28, 2020
Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia
October 15, 2020
Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease
August 24, 2020
Imara Reports Second Quarter 2020 Financial Results and Business Highlights
August 13, 2020
Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease
August 12, 2020
Imara to Webcast Conference Call of Second Quarter 2020 Financial Results
August 6, 2020
Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia
July 29, 2020
Imara Added to Membership of U.S. Small-Cap Russell 2000® Index
June 28, 2020
Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia
June 23, 2020
Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress
June 11, 2020
Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress
May 20, 2020
Imara Reports First Quarter 2020 Financial Results and Business Highlights
May 6, 2020
Imara Launches ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders
May 5, 2020
Imara Announces Appointment of Stephen M. Migausky as General Counsel
May 3, 2020
Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.
April 22, 2020
IMARA Announces Pricing of Initial Public Offering
March 10, 2020